Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AstraZeneca PLC Remuneration Information 2014

Mar 31, 2014

5229_dirs_2014-03-31_393c1d8b-f4ca-4b1a-98f9-9a5ac5889357.html

Remuneration Information

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5981D

AstraZeneca PLC

31 March 2014

Transaction by Person Discharging Managerial Responsibilities

Disclosure Rule DTR 3.1.4

On 28 March 2014, Dr Briggs Morrison, EVP, Global Medicines Development & Chief Medical Officer, a person discharging managerial responsibilities, was granted awards under the terms of the AstraZeneca Investment Plan (AZIP), the AstraZeneca Performance Share Plan (AZPSP) and the AstraZeneca Deferred Bonus Plan (AZDBP) over the Company's American Depositary Shares (ADSs) as detailed below.  One ADS equals one ordinary share.

Name Shares awarded under AZIP Shares awarded under AZPSP Shares awarded under AZDBP Award price per share
Briggs Morrison 4,004 24,025 2,173 $64.68

The AZIP award is subject to a four-year performance period (1 January 2014 to 31 December 2017) and a subsequent four-year holding period (1 January 2018 to 31 December 2021).

The AZPSP award is subject to a three-year performance period (1 January 2014 to 31 December 2016).

The AZDBP award is subject to a three-year holding period (28 March 2014 to 27 March 2017).

A summary of these plans and information about the performance measures that relate to the AZIP and AZPSP awards is set out in the Directors' Remuneration Report in the AstraZeneca Annual Report and Form 20-F Information 2013 which is available on the Company's website www.astrazeneca.com.

A C N Kemp

Company Secretary

31 March 2014

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSUARURSAAOOAR